Related Experiment Video

Updated: Oct 7, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease

A V Benjafield1, X L Wang, B J Morris

  • 1Department of Physiology and Institute for Biomedical Research, The University of Sydney, Australia.

Journal of Molecular Medicine (Berlin, Germany)
|May 19, 2001
PubMed

Insights

Genetic variations in the tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) gene are strongly associated with coronary artery disease (CAD). Specific alleles influence CAD risk and related factors like overweight and angina severity.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Immunology

Background:

  • Tumor necrosis factor (TNF)-alpha plays a role in coronary artery disease (CAD) pathophysiology.
  • TNF receptor 2 (TNFRSF1B) is implicated in mediating these effects and is linked to hypertension, high cholesterol, and insulin resistance.

Purpose of the Study:

  • To investigate the association between a microsatellite marker in the TNFRSF1B gene and the genetic basis of CAD.
  • To determine if specific TNFRSF1B alleles influence CAD risk and related clinical factors.

Main Methods:

  • A case-control study was conducted with 1006 CAD patients and 183 healthy controls.
  • A microsatellite marker (CA13-CA17) in intron 4 of TNFRSF1B was analyzed.
  • Statistical analyses included chi-squared tests, odds ratios, and stepwise logistic regression.

Main Results:

  • A significant association was found between the TNFRSF1B marker and CAD (P=0.00000069).
  • The CA16 allele was more frequent in CAD patients and associated with overweight.
  • The CA15 allele was less frequent in CAD patients, suggesting a protective effect.
  • Soluble TNFRSF1B levels were elevated in CAD patients and correlated with disease severity and other biomarkers.

Conclusions:

  • Genetic variation in or near the TNFRSF1B locus may predispose individuals to CAD.
  • TNFRSF1B genotype influences CAD risk, overweight, and angina severity.
  • Soluble TNFRSF1B levels are associated with CAD and may serve as a biomarker.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...